Mike Mensinger Sells 2,650 Shares of Beta Bionics (NASDAQ:BBNX) Stock

September 18, 2026 by InsiderTrades.com

Key Points

Beta Bionics insider Mark Hopman sold 30,779 shares at an average price of $20.13, generating $619,581.27 and reducing his ownership by 35.27%. The sale was made under a pre-arranged Rule 10b5-1 plan, following additional sales in September.
Beta Bionics recently received FDA clearance for its Mint patch pump, with a U.S. launch planned for the first quarter of 2027. The company also raised $172.5 million through a public offering to support commercialization, manufacturing, research and development, and working capital.
Despite positive product and financing developments, the offering may dilute existing shareholders, while fiscal 2026 revenue guidance of $121 million to $126 million is below analyst expectations. Analysts maintain a “Moderate Buy” consensus with an average price target of $21.90.

Beta Bionics, Inc. (NASDAQ:BBNX - Get Free Report) insider Mike Mensinger sold 2,650 shares of Beta Bionics stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $22.00, for a total value of $58,300.00. Following the completion of the sale, the insider directly owned 177,390 shares of the company's stock, valued at approximately $3,902,580. This trade represents a 1.47% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mike Mensinger also recently made the following trade(s):

On Wednesday, September 2nd, Mike Mensinger sold 4,375 shares of Beta Bionics stock. The shares were sold at an average price of $19.11, for a total transaction of $83,606.25.

Beta Bionics Stock Down 3.4%

Shares of NASDAQ:BBNX opened at $21.43 on Friday. The firm has a market capitalization of $964.14 million, a PE ratio of -12.99 and a beta of 3.37. The company has a 50-day moving average price of $17.56 and a two-hundred day moving average price of $13.99. Beta Bionics, Inc. has a twelve month low of $8.80 and a twelve month high of $32.71.

Beta Bionics (NASDAQ:BBNX - Get Free Report) last announced its quarterly earnings results on Wednesday, July 29th. The company reported ($0.53) EPS for the quarter, beating analysts' consensus estimates of ($0.62) by $0.09. The company had revenue of $32.01 million for the quarter. Beta Bionics had a negative net margin of 61.31% and a negative return on equity of 26.30%. Analysts anticipate that Beta Bionics, Inc. will post -2.05 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. The Goldman Sachs Group boosted their price objective on Beta Bionics from $17.00 to $19.00 and gave the company a "buy" rating in a research note on Wednesday, July 15th. Weiss Ratings raised Beta Bionics from a "sell (e+)" rating to a "sell (d-)" rating in a report on Tuesday, August 18th. Bank of America upped their price target on Beta Bionics from $18.00 to $20.00 and gave the company a "neutral" rating in a research report on Tuesday. UBS Group reissued a "buy" rating and issued a $25.00 price target on shares of Beta Bionics in a report on Tuesday. Finally, Robert W. Baird raised their price objective on shares of Beta Bionics from $14.00 to $16.00 and gave the company a "neutral" rating in a research report on Tuesday. Seven equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $21.90.

View Our Latest Analysis on Beta Bionics

Key Stories Impacting Beta Bionics

Here are the key news stories impacting Beta Bionics this week:

Positive Sentiment: The FDA cleared Beta Bionics’ Mint patch pump, expanding its diabetes-device portfolio beyond the iLet Bionic Pancreas. A full U.S. launch is planned for the first quarter of 2027, creating a potential second growth engine. Beta Bionics Stock Surges on FDA Clearance for Mint Patch Pump
Positive Sentiment: The company completed a public offering that raised $172.5 million in gross proceeds, including the underwriters’ full option exercise. The funds should support Mint commercialization, manufacturing, research and development, and working capital. Beta Bionics Announces Closing of $172.5 Million Public Offering
Positive Sentiment: Analyst sentiment remains generally favorable, with several firms raising price targets; the reported consensus rating is “Moderate Buy,” supported by optimism about Mint and the company’s longer-term growth prospects.
Neutral Sentiment: Insiders Mark Hopman and Mike Mensinger sold shares under pre-arranged Rule 10b5-1 plans. Hopman sold 30,779 shares for approximately $619,581, while Mensinger sold 2,650 shares for $58,300. Planned transactions do not necessarily signal a change in management’s outlook, but they may weigh on investor sentiment. Beta Bionics Insider Sells Stock
Negative Sentiment: The equity raise included millions of newly issued shares and pre-funded warrants priced at $17.25, creating meaningful dilution for existing shareholders and contributing to near-term selling pressure.
Negative Sentiment: Beta Bionics faces a securities class action alleging inadequate disclosures involving an FDA Form 483, a subsequent warning letter, quality-management and patient-safety issues, and unreported customer complaints. The allegations remain unproven, but the litigation adds regulatory, reputational and financial uncertainty. The lead-plaintiff deadline is November 3, 2026. BBNX Shareholder Alert
Negative Sentiment: Fiscal 2026 revenue guidance of $121 million to $126 million is below the approximately $133.9 million analyst consensus, indicating weaker near-term growth expectations.

Institutional Investors Weigh In On Beta Bionics

Several large investors have recently added to or reduced their stakes in the business. Squarepoint Ops LLC purchased a new position in Beta Bionics during the second quarter worth about $2,524,000. Bank of America Corp DE purchased a new stake in shares of Beta Bionics in the 2nd quarter valued at about $8,566,000. Man Group plc purchased a new stake in shares of Beta Bionics in the 2nd quarter valued at about $419,000. Legal & General Group Plc bought a new stake in shares of Beta Bionics during the 2nd quarter valued at about $62,000. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Beta Bionics during the 2nd quarter valued at about $172,000.

Beta Bionics Company Profile

(Get Free Report)

Beta Bionics, Inc is a medical technology company focused on developing automated insulin-delivery systems for people with diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to simplify diabetes management by using continuous glucose monitoring data to adjust insulin dosing with limited user input.

The iLet Bionic Pancreas received clearance from the U.S. Food and Drug Administration in 2023 for use by people with type 1 diabetes.